Operative Techniques in Orthopaedics
Volume 20, Issue 2 , Pages 136-143 , June 2010

Gene Therapy and Muscles: The Use of Adeno-associated Virus—Where are We Today?

  • Bing Wang, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Bing Wang, MD, PhD, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA 15261

References 

  1. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science. 1965;149:754–756
  2. Laughlin CA, Tratschin JD, Coon H, et al. Cloning of infectious adeno-associated virus genomes in bacterial plasmids. Gene. 1983;23:65–73
  3. Samulski RJ, Berns KI, Tan M, et al. Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A. 1982;79:2077–2081
  4. Srivastava A, Lusby EW, Berns KI. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol. 1983;45:555–564
  5. Xie Q, Bu W, Bhatia S, et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci U S A. 2002;99:10405–10410
  6. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther. 2008;8:911–922
  7. Frank KM, Hogarth DK, Miller JL, et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med. 2009;361:161–169
  8. Ding W, Zhang L, Yan Z, et al. Intracellular trafficking of adeno-associated viral vectors. Gene Ther. 2005;12:873–880
  9. Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol. 1996;70:8098–8108
  10. Athanasopoulos T, Graham IR, Foster H, et al. Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD). Gene Ther. 2004;11(suppl 1):S109–S121
  11. Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Mol Ther. 2006;13:241–249
  12. Hoffman EP, Dressman D. Molecular pathophysiology and targeted therapeutics for muscular dystrophy. Trends Pharmacol Sci. 2001;22:465–470
  13. Inui K, Okada S, Dickson G. Gene therapy in Duchenne muscular dystrophy. Brain Dev. 1996;18:357–361
  14. Kapsa R, Kornberg AJ, Byrne E. Novel therapies for Duchenne muscular dystrophy. Lancet Neurol. 2003;2:299–310
  15. Sweeney HL, Barton ER. The dystrophin-associated glycoprotein complex: What parts can you do without?. Proc Natl Acad Sci U S A. 2000;97:13464–13466
  16. van Deutekom JC, van Ommen GJ. Advances in Duchenne muscular dystrophy gene therapy. Nat Rev Genet. 2003;4:774–783
  17. Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther. 2006;14:452–455
  18. Penaud-Budloo M, Le Guiner C, Nowrouzi A, et al. Adeno-associated virus vector genomes persist as episomal chromatin in primate muscle. J Virol. 2008;82:7875–7885
  19. McCarty DM, Young SM, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004;38:819–845
  20. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255–256
  21. Schnepp BC, Clark KR, Klemanski DL, et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol. 2003;77:3495–3504
  22. Durocher Y, Pham PL, St-Laurent G, et al. Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J Virol Methods. 2007;144:32–40
  23. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224–2232
  24. Zhang H, Xie J, Xie Q, et al. Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production. Hum Gene Ther. 2009;20:922–929
  25. Virag T, Cecchini S, Kotin RM. Producing recombinant adeno-associated virus in foster cells: Overcoming production limitations using a baculovirus-insect cell expression strategy. Hum Gene Ther. 2009;20:807–817
  26. Thomas DL, Wang L, Niamke J, et al. Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene Ther. 2009;20:861–870
  27. Clement N, Knop DR, Byrne BJ. Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum Gene Ther. 2009;20:796–806
  28. Warrington KH, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum Genet. 2006;119:571–603
  29. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: Vector toolkit for human gene therapy. Mol Ther. 2006;14:316–327
  30. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr Gene Ther. 2005;5:285–297
  31. Schmidt M, Voutetakis A, Afione S, et al. Adeno-associated virus type 12 (AAV12): A novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity. J Virol. 2008;82:1399–1406
  32. Rodino-Klapac LR, Chicoine LG, Kaspar BK, et al. Gene therapy for duchenne muscular dystrophy: Expectations and challenges. Arch Neurol. 2007;64:1236–1241
  33. Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A. 2002;99:11854–11859
  34. Chirmule N, Xiao W, Truneh A, et al. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol. 2000;74:2420–2425
  35. Sun JY, Anand-Jawa V, Chatterjee S, et al. Immune responses to adeno-associated virus and its recombinant vectors. Gene Ther. 2003;10:964–976
  36. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med. 2006;12:342–347
  37. Choi VW, McCarty DM, Samulski RJ. AAV hybrid serotypes: Improved vectors for gene delivery. Curr Gene Ther. 2005;5:299–310
  38. Zhu T, Zhou L, Mori S, et al. Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation. 2005;112:2650–2659
  39. Gregorevic P, Blankinship MJ, Allen JM, et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 2004;10:828–834
  40. Inagaki K, Fuess S, Storm TA, et al. Robust systemic transduction with AAV9 vectors in mice: Efficient global cardiac gene transfer superior to that of AAV8. Mol Ther. 2006;14:45–53
  41. Pacak CA, Mah CS, Thattaliyath BD, et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res. 2006;99:e3–e9
  42. Wang Z, Zhu T, Qiao C, et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat Biotechnol. 2005;23:321–328
  43. Wang Z, Allen JM, Riddell SR, et al. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Hum Gene Ther. 2007;18:18–26
  44. Hauck B, Xiao W. Characterization of tissue tropism determinants of adeno-associated virus type 1. J Virol. 2003;77:2768–2774
  45. Schaffer DV, Maheshri N. Directed evolution of AAV mutants for enhanced gene delivery. Conf Proc IEEE Eng Med Biol Soc. 2004;5:3520–3523
  46. Yu CY, Yuan Z, Cao Z, et al. A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther. 2009;16:953–962
  47. Zhong L, Li B, Mah CS, et al. Next generation of adeno-associated virus 2 vectors: Point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A. 2008;105:7827–7832
  48. Qiao C, Zheng H, Yuan Z, et al. Comparison of transduction efficiency of tryosine-mutant AAV vectors in muscle. Mol Ther. 2009;17:S175
  49. Zhang W, Yue Y, Ghosh A, et al. Novel tryosine mutant vectors expand the utilities of AAV-mediated muscle gene therapy. Mol Ther. 2009;17:S176
  50. Dai J, Rabie AB. The use of recombinant adeno-associated virus for skeletal gene therapy. Orthod Craniofac Res. 2007;10:1–14
  51. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci U S A. 2000;97:13714–13719
  52. Wang B, Li J, Qiao C, et al. A canine minidystrophin is functional and therapeutic in mdx mice. Gene Ther. 2008;15:1099–1106
  53. Hauck B, Zhao W, High K, et al. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J Virol. 2004;78:13678–13686
  54. Le Bec C, Douar AM. Gene therapy progress and prospects—Vectorology: Design and production of expression cassettes in AAV vectors. Gene Ther. 2006;13:805–813
  55. McCarty DM, Monahan PE, Samulski RJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther. 2001;8:1248–1254
  56. Wang Z, Ma HI, Li J, et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 2003;10:2105–2111
  57. Li J, Sun W, Wang B, et al. Protein trans-splicing as a means for viral vector-mediated in vivo gene therapy. Hum Gene Ther. 2008;19:958–964
  58. Duan D, Yue Y, Yan Z, et al. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat Med. 2000;6:595–598
  59. Nakai H, Storm TA, Kay MA. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat Biotechnol. 2000;18:527–532
  60. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat Med. 2000;6:599–602
  61. Tafuro S, Ayuso E, Zacchigna S, et al. Inducible adeno-associated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res. 2009;83:663–671
  62. Jazwa A, Jozkowicz A, Dulak J. New vectors and strategies for cardiovascular gene therapy. Curr Gene Ther. 2007;7:7–23
  63. Judge LM, Chamberlain JS. Gene therapy for Duchenne muscular dystrophy: AAV leads the way. Acta Myol. 2005;24:184–193
  64. Watchko J, O'Day T, Wang B, et al. Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum Gene Ther. 2002;13:1451–1460
  65. Gregorevic P, Allen JM, Minami E, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med. 2006;12:787–789
  66. Wang B, Li J, Fu FH, et al. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J Orthop Res. 2009;27:421–426
  67. Wang Z, Kuhr CS, Allen JM, et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther. 2007;15:1160–1166
  68. Monahan PE, Samulski RJ, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. 1998;5:40–49
  69. Li J, Dressman D, Tsao YP, et al. rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. Gene Ther. 1999;6:74–82
  70. Xiao X, Li J, Tsao YP, et al. Full functional rescue of a complete muscle (TA) in dystrophic hamsters by adeno-associated virus vector-directed gene therapy. J Virol. 2000;74:1436–1442
  71. Melo LG, Agrawal R, Zhang L, et al. Gene therapy strategy for long-term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene. Circulation. 2002;105:602–607
  72. Yue Y, Li Z, Harper SQ, et al. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation. 2003;108:1626–1632
  73. Chu D, Thistlethwaite PA, Sullivan CC, et al. Gene delivery to the mammalian heart using AAV vectors. Methods Mol Biol. 2004;246:213–224
  74. Kaspar BK, Roth DM, Lai NC, et al. Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J Gene Med. 2005;7:316–324
  75. Wang B, Li J, Fu FH, et al: Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. J Orthop Res (in press)
  76. Greelish JP, Su LT, Lankford EB, et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat Med. 1999;5:439–443
  77. Hartigan-O'Connor D, Kirk CJ, Crawford R, et al. Immune evasion by muscle-specific gene expression in dystrophic muscle. Mol Ther. 2001;4:525–533
  78. Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, et al. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 2002;9:1576–1588
  79. Harms JS, Splitter GA. Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. Hum Gene Ther. 1995;6:1291–1297
  80. Donoviel DB, Shield MA, Buskin JN, et al. Analysis of muscle creatine kinase gene regulatory elements in skeletal and cardiac muscles of transgenic mice. Mol Cell Biol. 1996;16:1649–1658
  81. Larochelle N, Oualikene W, Dunant P, et al. The short MCK1350 promoter/enhancer allows for sufficient dystrophin expression in skeletal muscles of mdx mice. Biochem Biophys Res Commun. 2002;292:626–631
  82. Shield MA, Haugen HS, Clegg CH, et al. E-box sites and a proximal regulatory region of the muscle creatine kinase gene differentially regulate expression in diverse skeletal muscles and cardiac muscle of transgenic mice. Mol Cell Biol. 1996;16:5058–5068
  83. Weeratna RD, Wu T, Efler SM, et al. Designing gene therapy vectors: Avoiding immune responses by using tissue-specific promoters. Gene Ther. 2001;8:1872–1878
  84. Brennan KJ, Hardeman EC. Quantitative analysis of the human alpha-skeletal actin gene in transgenic mice. J Biol Chem. 1993;268:719–725
  85. Hakimi P, Yang J, Casadesus G, et al. Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem. 2007;282:32844–32855
  86. Dunant P, Larochelle N, Thirion C, et al. Expression of dystrophin driven by the 1.35-kb MCK promoter ameliorates muscular dystrophy in fast, but not in slow muscles of transgenic mdx mice. Mol Ther. 2003;8:80–89
  87. Wang B, Li J, Fu FH, et al. Construction and analysis of compact muscle-specific promoters for AAV vectors. Gene Ther. 2008;15:1489–1499
  88. Hauser MA, Robinson A, Hartigan-O'Connor D, et al. Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol Ther. 2000;2:16–25
  89. Cordier L, Hack AA, Scott MO, et al. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol Ther. 2000;1:119–129
  90. Jaynes JB, Johnson JE, Buskin JN, et al. The muscle creatine kinase gene is regulated by multiple upstream elements, including a muscle-specific enhancer. Mol Cell Biol. 1988;8:62–70
  91. Salva MZ, Himeda CL, Tai PW, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther. 2007;15:320–329
  92. Draghia-Akli R, Fiorotto ML, Hill LA, et al. Myogenic expression of an injectable protease-resistant growth hormone-releasing hormone augments long-term growth in pigs. Nat Biotechnol. 1999;17:1179–1183
  93. Li X, Eastman EM, Schwartz RJ, et al. Synthetic muscle promoters: Activities exceeding naturally occurring regulatory sequences. Nat Biotechnol. 1999;17:241–245
  94. Ehmsen J, Poon E, Davies K. The dystrophin-associated protein complex. J Cell Sci. 2002;115:2801–2803
  95. Emery AE. The muscular dystrophies. Lancet. 2002;359:687–695
  96. Trollet C, Athanasopoulos T, Popplewell L, et al. Gene therapy for muscular dystrophy: Current progress and future prospects. Expert Opin Biol Ther. 2009;9:849–866
  97. Crawford GE, Faulkner JA, Crosbie RH, et al. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J Cell Biol. 2000;150:1399–1410
  98. Harper SQ, Hauser MA, DelloRusso C, et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8:253–261
  99. Liu M, Yue Y, Harper SQ, et al. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther. 2005;11:245–256
  100. Fabb SA, Wells DJ, Serpente P, et al. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet. 2002;11:733–741
  101. Kornegay J, Li J, Bogan J, et al. Widespread muscle expression of an AAV-9 human mini-dystrophin construct after systemic intravenous injection in golden retriever muscular dystrophy (GRMD) neonatal dogs. Mol Ther. 2009;17:S152
  102. Li J, Bogan J, Chen C, et al. Hydrodynamic limb vein injection of AAV9 results in regional and systemic long-term expression of minidystrophin in young adult GRMD dogs. Mol Ther. 2009;17:S278
  103. Arnett AL, Chamberlain JR, Chamberlain JS. Therapy for neuromuscular disorders. Curr Opin Genet Dev. 2009;19:290–297
  104. Nakamura A, Takeda S. Exon-skipping therapy for Duchenne muscular dystrophy. Neuropathology. 2009;29:494–501
  105. Goyenvalle A, Vulin A, Fougerousse F, et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science. 2004;306:1796–1799
  106. Denti MA, Rosa A, D'Antona G, et al. Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model. Proc Natl Acad Sci U S A. 2006;103:3758–3763
  107. Cossu G, Sampaolesi M. New therapies for Duchenne muscular dystrophy: Challenges, prospects and clinical trials. Trends Mol Med. 2007;13:520–526
  108. Goyenvalle A, Babbs A, van Ommen GJ, et al. Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy. Mol Ther. 2009;17:1234–1240
  109. Denti MA, Incitti T, Sthandier O, et al. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther. 2008;19:601–608
  110. Howard MT, Shirts BH, Petros LM, et al. Sequence specificity of aminoglycoside-induced stop condon readthrough: Potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol. 2000;48:164–169
  111. van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med. 2007;357:2677–2686
  112. Tal J. Adeno-associated virus-based vectors in gene therapy. J Biomed Sci. 2000;7:279–291

 The authors declare no conflicts of interest and have received no payment for the preparation of this manuscript.

PII: S1048-6666(09)00164-5

doi: 10.1053/j.oto.2009.10.011

Operative Techniques in Orthopaedics
Volume 20, Issue 2 , Pages 136-143 , June 2010

Article Tools

* Image Usage & Resolution